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Abstract
Background: Recent genome-wide association studies (GWAS) have identified common variants in the UMOD region
associated with kidney function and disease in the general population. To identify novel rare variants as well as common
variants that may account for this GWAS signal, the exons and 4 kb upstream region of UMOD were sequenced.
Methodology/Principal Findings: Individuals (n=485) were selected based on presence of the GWAS risk haplotype and
chronic kidney disease (CKD) in the ARIC Study and on the extremes of of the UMOD gene product, uromodulin, in urine
(Tamm Horsfall protein, THP) in the Framingham Heart Study (FHS). Targeted sequencing was conducted using capillary
based Sanger sequencing (3730 DNA Analyzer). Variants were tested for association with THP concentrations and estimated
glomerular filtration rate (eGFR), and identified non-synonymous coding variants were genotyped in up to 22,546 follow-up
samples. Twenty-four and 63 variants were identified in the 285 ARIC and 200 FHS participants, respectively. In both studies
combined, there were 33 common and 54 rare (MAF,0.05) variants. Five non-synonymous rare variants were identified in
FHS; borderline enrichment of rare variants was found in the extremes of THP (SKAT p-value=0.08). Only V458L was
associated with THP in the FHS general-population validation sample (p=9*10
23, n=2,522), but did not show direction-
consistent and significant association with eGFR in both the ARIC (n=14,635) and FHS (n=7,520) validation samples.
Pooling all non-synonymous rare variants except V458L together showed non-significant associations with THP and eGFR in
the FHS validation sample. Functional studies of V458L revealed no alternations in protein trafficking.
Conclusions/Significance: Multiple novel rare variants in the UMOD region were identified, but none were consistently
associated with eGFR in two independent study samples. Only V458L had modest association with THP levels in the general
population and thus could not account for the observed GWAS signal.
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Chronic kidney disease affects 5–10% of adults worldwide [1],
and is associated with an increased risk of cardiovascular
morbidity and mortality [2,3] as well as end-stage renal disease
[4,5]. Using genome-wide association studies (GWAS), we and
others have previously identified common variants in the UMOD
gene region on chromosome 16 that are associated with measures
of kidney function, including estimated glomerular filtration rate
(eGFR), serum creatinine, and chronic kidney disease (CKD)
[6,7,8,9,10]. The role of the UMOD gene in the etiology of kidney
diseases is further supported by rare UMOD variants causing
monogenic forms of cystic kidney disease (MIM #162000,
#603860, #609886) [11,12].
The UMOD gene is exclusively transcribed in the kidney and
encodes Tamm Horsfall protein, also known as uromodulin, the
most abundant protein in the urine of healthy individuals [13].
Both rare monogenic disease-causing mutations and common
variants identified by GWAS lead to altered concentrations of
urinary uromodulin [10,14,15]. Whereas urinary uromodulin
concentrations are typically reduced in the urine of individuals
with monogenic forms of UMOD-associated disease [16],
individuals carrying the CKD risk-increasing variants identified
in GWAS have higher amounts of urinary uromodulin concen-
trations [10,14,17].
Genome-wide association studies pinpoint genetic regions
rather than causal variants. The objective of this study was
therefore to sequence UMOD exonic, regulatory and conserved
regions in several hundred participants of the Framingham Heart
Study (FHS) and the Atherosclerosis Risk in Communities Study
(ARIC) selected based on extremes of urinary uromodulin
concentrations (FHS) and CKD status and UMOD haplotype
surrounding the GWAS signal (ARIC). Variants that were
associated with kidney phenotypes or resulted in amino acid
changes were genotyped in the entire FHS and ARIC studies in
order to assess whether any of them may account for the GWAS
signal and to confirm and evaluate novel rare variants that may
help to explain disease risk.
Methods
Ethics Statement
Participants from both the FHS and the ARIC studies provided
written informed consent and the institutional review boards from
the coordinating institutions approved the study.
Study samples
The Framingham Heart Study, initiated in 1948, is a
community-based longitudinal study. The original cohort of
5,209 participants were randomly enrolled from Framingham,
Massachusetts, United States [18]. In 1971, 5,124 children of the
original cohort, and children’s spouses, were enrolled and referred
as the offspring cohort [19]. In 2002, the third generation cohort,
4,095 children of the offspring cohort, was recruited [20]. Most
FHS participants are self-identified as Caucasian (white). Among
them, genome-wide SNP genotyping of 9,274 participants from all
three generations was performed using the Affymetrix 500 K
mapping array and the Affymetrix 50 K supplemental array. The
study sample for the current study is a subset of individuals
attending the Framingham offspring cohort exam 6 (1995–1998)
with urinary uromodulin levels (n=2,948) and with eGFR
(n=3,452) measured, as well as individuals attending the original
cohort exam 15 with eGFR levels (n=2,538) and the third
generation with eGFR levels (n=4,067). Urinary uromodulin
concentrations were measured via immunoassay with a bead
Luminex platform (Rules Based Medicine, Austin, TX); the inter-
assay coefficient of variation (CV) is 5.0% at a mean concentration
of 37 ug/ml and 11.4% at a mean concentration of 9.4 ug/ml.
Urinary creatinine was measured using the modified Jaffe ´ method
by a morning single-void urine sample. Urinary uromodulin was
indexed to creatinine as uromodulin-to-creatinine ratio in order to
account for differences in urine concentration.
The Atherosclerosis Risk in Communities Study is an ongoing
population-based study that enrolled individuals at four US study
sites from 1987–89 [21]. Individuals were interviewed and
examined at four study visits, approximately every three years.
Detailed information on demographics, cardiovascular risk factors
and co-morbidities is available and has been described previously
[21]. For the current study, data was analyzed from the fourth
study visit (1996–98).
In both studies, serum creatinine was measured using a Jaffe
method and calibrated to nationally representative estimates as
described previously [22]. GFR was estimated using the 4-variable
MDRD Study equation [23]. CKD was defined as eGFR
,60 ml/min/1.73 m
2 as described in the GWAS publication
that identified the association between common UMOD variants
and CKD [6].
Selection of individuals for sequencing
In the FHS Study, 50 men and 50 women of European ancestry
were selected from each extreme of the urinary uromodulin-to-
creatinine ratio, for a total of 200 individuals. This design allows
for identifying variants in UMOD that lead to both extremely high
and low concentrations of urinary uromodulin.
In the ARIC Study, 285 individuals of European ancestry were
selected based on the presence or absence of CKD as well as on
the 8-SNP haplotype identified from GWAS (rs12917707,
rs12922822, rs13329952, rs13333226, rs4293393, rs13335818,
rs9928936, rs9928757; high CKD-risk haplotype marked by the
common C allele at rs12917707) [6]. In total, we sequenced 96 of
320 individuals with CKD and homozygous for the at-risk
haplotype, 95 of 2,193 individuals without CKD (defined as
eGFR between 80 and 120 ml/min/1.73 m
2) and homozygous
for the at-risk haplotype, and 94 of 101 individuals without CKD
and homozygous for the protective haplotype; there were too few
individuals to select from the group with CKD and homozygous
for the protective haplotype (n=11). This selection scheme
enhanced our ability to identify single common variants that
could account for the observed GWAS signal.
Sequencing and Follow-up Genotyping
Sequencing of the UMOD exons and the 4 kb upstream region
including putative regulatory elements was conducted for the FHS
samples using Sanger sequencing on a ABI 3730 Capillary
Sequencer at Beckman Coulter Genomics. Twenty-two amplicons
were used to cover the sequenced region on chromosome 16; the
coordinates of the sequenced region were 20368293-20367780,
20367984-20367476, 20367640-20367050, 20367305-20366749,
20366892-20366350, 20366480-20365913, 20366084-20365491,
20365633-20365045, 20365258-20364659, 20364911-20364313,
20364453-20363910, 20362361-20361850, 20360710-20360211,
20360359-20359766, 20359909-20359435, 20357762-20357178,
20355642-20355199, 20352794-20352346, 20349081-20348482,
20348413-20347818, 20347024-20346523, and 20344820-
20344290. Three out of 63 SNPs were excluded from association
analyses by applying Polyphred score threshold 99 or above that
corresponds to 97% true positive rate of a SNP calling (http://
droog.mbt.washington.edu/poly_doc50.html).
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using capillary-based Sanger sequencing (3730xl DNA Analyzer)
at the University of Texas Health Science Center at Houston.
UMOD exons were resequenced using the VariantSEQr platform
(16 amplicons), which allows amplification of exons with similar
PCR conditions and sequencing with a single universal primer.
The UMOD upstream region not covered by VariantSEQr was
amplified using custom designed primers (one amplicon). The
positions of the sequenced regions were 20367823-20367620,
20365191-20363719, 20362316-20361844, 20360580-20359395,
20357704-20357239, 20355525-20355309, 20352722-20352486,
20349045-20348548, 20348307-20347844, 20347060-20346650,
and 20344840-20344114 (NC_000016.9 GRCh37.p5 coordi-
nates). Variants were identified using the Lasergene v8 SeqMan
assembler, and SNP traces visually verified for all subjects at
putative SNP sites. One subject was excluded due to .50%
missing data, and one variant was excluded due to a call rate
,70%. Sequencing primers for both studies are available upon
request.
All non-synonymous coding variants as well as novel associated
variants in the putative promoter region were selected for follow-
up genotyping in the respective discovery study. In FHS, the five
non-synonymous coding variants as well as the upstream variant
g.20364263C.T were genotyped among n=7,567 with GFR and
n=2,522 with available urinary uromodulin data. In ARIC, the
non-synonymous coding variant V458L, the upstream variant
rs28362063 and rs111699931 in the 39 UTR were followed up
among 14,635 individuals. Figure S1 shows a flow chart of the
study design.
Follow-up genotyping of selected variants in both ARIC and
FHS was conducted using Taqman assays at the University of
Texas Health Science Center at Houston. Concordance of a set of
62 samples genotyped in duplicate was 100%. Genotyping quality
control metrics for the variants are provided in Table S1.
Genotyping quality was high, and all rare variants identified
through sequencing were confirmed by genotyping, even in cases
where just one copy of the alternate allele had been observed in
the sequence data.
Functional studies of variant effect on uromodulin
polymerization and trafficking
HA-tagged uromodulin isoforms were expressed from pcDNA
3.1(+) (Invitrogen, Carlsbad, CA) as previously described [24]. The
V458L variant was obtained by using the Quickchange mutagen-
esis kit (Stratagene, La Jolla, CA) following the manufacturer’s
instructions (primers available upon request). The construct was
fully sequenced to verify the mutagenesis. The protocols for the
generation of stably transfected cells, western blot and immuno-
fluorescence analyses have been previously described [24].
Antibodies used were mouse monoclonal anti-HA (Covance
Research Products, Princeton, NJ), mouse monoclonal anti-alpha
tubulin (Santa Cruz Biotechnology, Santa Cruz, CA), and rabbit
polyclonal anti-calnexin (Sigma-Aldrich, Saint Louis, MO).
Statistical analyses
Study sample characteristics were compared among the groups
selected for sequencing using t-test and ANOVA for continuous
variables and chi-square test for categorical variables.
Associations with the urinary uromodulin-to-creatinine ratio,
GFR and CKD in the sequenced samples were evaluated using
linear and logistic regression models assuming an additive genetic
model. In ARIC, p-values for variants with MAF,0.05 were
obtained using adaptive permutation. Both the urinary uromodu-
lin-to-creatinine ratio and eGFR were analyzed using a natural
logarithmic transformation due to their skewed nature. Through-
out this manuscript, ‘‘THP’’ is used to refer to the ln(urinary
uromodulin to creatinine ratio).
For the follow-up analyses of the genotyped variants, linear
regression was used to evaluate the associations between genotype
and THP and eGFR levels. In both studies, analyses were adjusted
for age, sex, cohort status (FHS only) and study center (ARIC
only), and an additive genetic model was used. In FHS, empirical
p-values from testing simulated genotypes according to family
relationships with observed phenotypes were reported to account
for phenotypic correlation due to family relationship.
Cumulative effects of multiple rare variants on THP concen-
trations adjusted for age, sex and cohort status were tested using
the sequence kernel association test (SKAT) [25].
The expected proportion of variants discovered was calculated
using the method in Li and Leal 2009 [26]. Post-hoc power was
calculated for detecting significant associations for variants
brought forward to follow-up genotyping.
Results
Variants Identified through Sequencing
Characteristics of the individuals selected for sequencing are
presented by study and group of high or low selection criterion
(THP, CKD) in Table 1.
Table 2 provides an overview of the variants identified through
sequencing. In the 200 individuals from the FHS Study, 63
variants in UMOD exons as well as the entire 4 kb upstream region
were identified. In the 285 sequenced samples from the ARIC
Study, 24 variants in UMOD exons, upstream and conserved 59
regions were identified. Most of the additional variants found in
FHS were due to the larger sequenced upstream region. In both
studies, more than half of the identified variants were of low
frequency (MAF,0.05), and about 25% of variants in both studies
are not contained in the current publicly available databases
(dbSNP Build 134, release August 15, 2011). There were 4
synonymous coding variants identified in both studies, and 5 non-
synonymous coding variants, one found in both studies and 4
exclusively in the FHS Study (Table 2). Figure 1 shows an
overview of all identified variants and their localizations with
respect to the UMOD gene. All variants identified through
sequencing as well as their associations with eGFR (ARIC) and
THP (FHS) are listed in Tables S2 and S3. Although different
primary phenotypes were analyzed in the two studies, the same
variants showed significant associations with eGFR (ARIC) and
THP (FHS) (Figure 1). Of the 17 variants present in both studies,
all 11 variants with MAF.0.05 showed associations with either
higher THP in FHS and lower GFR in ARIC, or with lower THP
in FHS and higher GFR in ARIC, consistent with earlier GWAS
findings. This was also the case for 4 of the 6 rare variants found in
both studies (compare Tables S2 and S3).
Follow-up genotyping in population-based studies
Table 3 provides an overview of the variants selected for
follow-up genotyping, including any resulting amino acid substi-
tutions and information about functional prediction. Both
predicition softwares Polyphen2 and SIFT classified the V458L,
T469M, and H565R as damaging, whereas R142Q, located in the
third epidermal growth factor domain of uromodulin, and F639S
were classified as benign. In FHS, all non-synonymous coding
variants, as well as any novel rare eGFR- or THP-associated
variants in the upstream region were followed up (total of 6
variants). Figure 2 shows the haplotypes formed by these 6 rare
variants as well as 6 common variants that are tag SNPs for the
UMOD Gene Sequencing and Kidney Disease
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pants, in order to assess whether rare alleles leading to non-
synonymous amino acid changes always occur on the same
haplotypic background. Although the rare allele leading to the
V458L change that was associated with higher THP concentra-
tions was always found on the high-risk haplotype identified in
GWAS, there were also rare alleles associated with lower THP
identified on the high-risk GWAS haplotype (T469M). In ARIC,
all non-synonymous coding variants as well as novel common
variants in the conserved 39 or 59 region of the UMOD gene or
falling into a predicted transcription factor binding site were
followed up (total of 3 variants). Of the five non-synonymous
coding variants typed between the two studies, four had already
been deposited in dbSNP 134 [27] or identified through other
sequencing efforts [28].
Table 1. Characteristics of the study samples used for sequencing.
Framingham Heart Study ARIC Study
Low THP levels
(n=100)
High THP
levels
(n=100) P-value Cases (n=96)
Controls
low risk
hap (n=94)
Controls high
risk hap
(n=95)
P-
value
Age, years 55.8(9.0) 59.0(9.7) 0.017 66. (6) 64 (6) 63 (5) 0.0004
Uromodulin (ug/ml) 0.23(0.30) 34.6(26.1) ,.0001 NA NA NA NA
Uromodulin/U-creatinine
ratio
0.0018(0.0019) 0.41(0.23) ,.0001 NA NA NA NA
% female (n) 50.0*(50) 50.0*(50) 1 60.4 (58) 47.9 (45) 51.6 (49) 0.2
% HTN (n) 42.0(42) 34.0(34) 0.25 59.4 (57) 35.1 (33) 29.5 (28) ,0.001
%D M( n ) 10.0(10) 3.0(3) 0.045 13.5 (13) 20.4 (19) 10.5 (10) 0.15
BMI, kg/m2 29.8(6.2) 27.1(4.3) 0.0003 28.7 (4.6) 28.1 (4.9) 27.2 (4.6) 0.11
GFR, ml/min/1.73 m
2 94.7(24.0) 90.0(25.4) 0.18 54.3 (7.2) 85.5 (12.0) 86.7 (14.0) ,0.001
UACR (mg/g) 2.5(2.8) 30.8(96.8) 0.004 5.9 (5.6) 5.8 (5.1) 4.6 (3.9) 0.1
For continuous variables, the standard deviation is shown in parentheses; for dichotomous variables, this is the n.
*matched by design. Abbreviations: HTN: hypertension; DM: diabetes mellitus; BMI: body mass index; GFR: glomerular filtration rate; UACR: urinary albumin to creatinine
ratio. P-values for differences across the three groups in ARIC are obtained by ANOVA or chi
2 tests.
doi:10.1371/journal.pone.0038311.t001
Figure 1. Structure of the UMOD gene and localization of the variants identified through sequencing as well as their association
with phenotypes. In the UMOD gene, exons are indicated as black boxes and 39 and 59 UTR as gray boxes. Identified variants are shown as a rug
mark on top of the gene, common variants that comprised the initial GWAS signal are shown as the upper part of the rug mark and are highlighted in
gray if non-exonic. Non-synonymous variants are indicated. In the lower part, variants that are identified in both studies are connected with a gray
dotted line, with their 2log10(p-value) for association with eGFR (ARIC) and THP (FHS) shown on the ordinate.
doi:10.1371/journal.pone.0038311.g001
UMOD Gene Sequencing and Kidney Disease
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The association between eGFR and each variant in the follow-
up samples are provided in Tables 4 (FHS) and 5 (ARIC). Only
V458L was nominally associated; each copy of the minor T allele
was associated with lower eGFR (p=0.046) in ARIC. Conversely,
the association with higher eGFR in FHS was not significant
(p=0.07). In the ARIC Study, V458L was not able to account for
the GWAS signal. The r
2 and D9 between the V458L and
rs12917707, tagging the original GWAS signal, in the entire ARIC
European-ancestry sample was 0.002 and 0.735, respectively.
Moreover, the inclusion of V458L in a regression model that
already contained rs12917707 did not explain additional variance
of eGFR (2.7% in model with rs12917707 alone and 2.8% in a
model with rs12917707 and V458L) nor did it appreciably change
each SNP’s beta estimates and p values. In FHS, the minor allele
of g.20364263 was associated with higher levels of eGFR
(p=7610
23), but only 2 copies of the minor allele were present
in 7,520 FHS individuals.
Table 4 also shows the association between the genotyped
variants and THP in the FHS Study. Significant associations were
found between the minor T allele of V458L and higher THP
(p=9*10
23), as well as the minor G allele of H565R and lower
THP (p=0.02). When conducting the SKAT burden test among
the entire genotyped population to test for the cumulative effects of
all rare variants, the test was significant (p=0.007). Excluding
V458L and g.20364263C.T from the burden test, as the first
variant has a minor allele frequency of 0.03 and the second variant
is not located within the gene, yielded a non-significant p-value
(p=0.29).
In the FHS Study, the previously published GFR-associated
variant from GWAS, rs12917707, explained 2.3% of the THP
variance. Together, the 6 genotyped rare variants explained only
an additional 0.5% of variance. We also examined if any
additional sequence SNPs in the UMOD promoter region
explained additional variation in the presence of the GWAS
Table 2. Summary of Variants Identified via sequencing in
each study.
FHS ARIC
n (individuals) 200 285
% missing data 2.8 7.1
# variants (common/rare*) 63 (22/41) 24 (11/13)
# variants with rs number 46 (22/24) 18 (11/7)
# synonymous coding variants 4 (3/1) 4 (3/1)
# non-synonymous coding variants 5 (0/5) 1 (0/1)
*rare in this context is defined as MAF,0.05. Known variants are based on
dbSNP134, HRG37.2. Of all variants identified in total, 17 were identified in both
studies (7 rare/10 common [referring to FHS minor allele frequency]). Of these,
four variants were synonymous coding (3 common, 1 rare) and one non-
synonymous coding.
doi:10.1371/journal.pone.0038311.t002
Figure 2. Haplotypes at the UMOD locus in the 200 sequenced FHS participants. Haplotypes are composed of the 6 rare variants detected
in this study (bold) and 6 common variants tagging the GWAS signal. Frequencies of each haplotype are provided to the right, and the haplotypes
containing the high CKD-risk allele at rs12917707 (C) are shaded in gray. Rare alleles associated in this study with lower THP concentrations are shown
in light blue, and rare alleles associated with higher THP concentrations are shown in dark blue.
doi:10.1371/journal.pone.0038311.g002
UMOD Gene Sequencing and Kidney Disease
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26 in the sequenced sample). SNPs
that remained nominally significant (p=0.03) and therefore
contributed to explaining additional THP variance after adjusting
for rs12917707 were rs115312009, rs147825435, rs76619864, and
rs75432530.
Functional assessment of the V458L variant
In our study, the V458L variant was the only rare variant that
showed association with both THP concentrations (FHS) and
eGFR (ARIC). Therefore, we evaluated whether the V458L
variant would show characteristics typical of variants causing
monogenic UMOD disease, since patients with rare UMOD
mutations show lower urinary uromodulin levels, which are
caused by incorrect protein folding, trafficking and aggregation.
The low frequency variant V458L leads to an amino acid
substitution of valine to leucine at position 458 in exon 7 of
UMOD and is predicted to have a damaging effect on protein
function by both PolyPhen-2 [29] and SIFT [30]; three other
patient mutations in monogenic UMOD diseases have been
described in exon 7 [16,31].
In stably transfected MDCK cells the UMOD V458L variant
did not show any significant difference relative to wild-type
protein. Indeed, it reached the plasma membrane in comparable
amount, it assembled into extracellular filaments (Figure 3A) and
it was not enriched in the ER, as opposed to the patient mutation
C150S with a known trafficking defect [32] (Figure 3B, C).
Discussion
In our study of targeted sequencing of coding and conserved
portions of the UMOD gene region, we did not identify any
common non-synonymous coding variant that could account for
the GWAS signal by itself. Rare variants were identified and
verified, but they were not significantly enriched among individ-
uals at the extremes of THP levels when the entire study
population was considered. The V458L variant, which is predicted
to have a damaging effect on protein function, showed significant
association with eGFR in one but not both studies, association
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Table 5. Associations between genotyped variants identified
from sequencing brought forward to the entire ARIC sample
and ln(eGFR).
rs28362063
rs55772253
(V458L) rs111699931
ARIC white
Alleles (major/
minor)
A/G G/T C/T
effect, per allele 0.015 20.021 0.002
se 0.004 0.010 0.008
p-value 4.98E-05 0.045 0.77
n 10871 10823 10905
ARIC black
Alleles (major/
minor)
A/G G/T C/T
effect, per allele 20.007 0.047 0.038
se 0.015 0.054 0.039
p-value 0.66 0.39 0.33
n 3853 3812 3860
doi:10.1371/journal.pone.0038311.t005
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aggregation or trafficking as observed for monogenic disease-
causing variants.
Interpretation of association results
Several potential reasons exist for our observations. First, there
may not be any moderately-to-highly penetrant rare UMOD
variants associated with the common, complex phenotypes under
study. Second, we only focused on sequencing the exons of
UMOD and the 4 kb upstream region. Even though our GWAS
signal was localized to the promoter region upstream of UMOD,
it is possible that the causal, possibly non-SNP, variant localizes
to the non-coding regions of the gene or beyond the 4 kb
upstream region. Third, we sequenced approximately 200–300
individuals from each study, and thus may have missed other
rare variants. For a sequenced sample size of 94–100 in each of
the case/control groups, we expect to discover 85% of all
variants with MAF.1% and 64% of all variants with
MAF.0.5%. The percentage of trait variance explained by the
rare SNPs ranged from 5*10
28 for H565R for eGFR in FHS to
0.27% for V458L for THP concentrations in FHS (median
0.042%). At a nominal alpha level of 0.05, to achieve 80%
power, the required sample size is 2,900 for detecting a SNP
explaining 0.27% of the trait variance, and 18,550 for 0.042% of
the trait variance. It is therefore possible that we were
underpowered to identify robust associations of some of our
newly identified rare variants in the general population. Even so,
our results indicate that none of the identified rare SNPs had a
large effect on the phenotypes. Finally, in terms of the
unchanged functional effects of the V458L variant, the variant
may exert its effects on THP concentrations and possibly renal
function through a different mechanism than the one known for
monogenic disease and that is not studied in the present study.
In the context of monogenic uromodulin-associated
kidney diseases
The rare non-synonymous coding variants R142Q, T469M,
H565R, and F639S in UMOD identified in the FHS Study had not
previously been described in reports of patients with rare
autosomal-dominant uromodulin-associated diseases. Recently,
the largest description of kidney disease patients with UMOD
mutations to date was published [31]. In this report, the authors
also identified the T469M variant, which they classified as a
patient variant defined as a missense mutation affecting a highly
conserved nucleotide and absent in 300 control chromosomes. In
our study, we observed 25 carriers of one copy of the T469M
minor allele out of a total of 7,919 genotyped FHS participants.
The Mendelian forms of uromodulin-associated disease exhibit an
autosomal-dominant mode of inheritance, and the median renal
survival in individuals with Mendelian forms of disease is estimated
at 54 years [31]. As none of the carriers of the T469M minor allele
had end-stage renal disease, our results suggest that either T469M
may not be a causal variant for Mendelian forms of uromodulin-
associated disease, or it is a mild one with a modest effect on renal
survival.
Comparison to other similar studies
Several previous studies have re-sequenced candidate genes
identified through GWAS in order to identify novel rare genetic
variants with potentially stronger associations with the phenotype
than observed for the trait-associated variants in GWAS. More
successfulrecent examplesintheareaofcommon,complexdiseases
include uric acid and gout [33] and inflammatory bowel disease.
Using 350 cases of Crohn’s disease and controls, investigators were
able to identify multiple independent rare variants in 7 genes, some
with large effect sizes [34]. Similar to the present study, the variants
identified did not account for the original GWAS signal. However,
less success has been observed for many other common complex
diseases, including fine-mapping of the 9p21 region in association
with type 2 diabetes and coronary artery disease [35], and type 1
diabetes [36]. There are currently many ongoing sequencing efforts
that are focused on sequencing the exonsof candidate genes, as well
as whole-exome sequencing. The relative yield of this approach, as
comparedtowholegenomesequencingandassessmentofstructural
variation, remains unknown.
Conclusion
Multiple novel rare non-synonymous coding variants in the
UMOD region were identified, but none were consistently
associated with eGFR. Only V458L had modest association with
THP levels in the general population and thus could not account
for the observed GWAS signal.
Supporting Information
Figure S1 Flow chart of the study design.
(TIF)
Figure 3. Analysis of trafficking and polymerization of
uromodulin variant V458L. Immunofluorescence showing uromo-
dulin distribution in MDCK cells stably expressing HA-tagged wild-type
or V458L isoforms. Bar=20 mm. (a) Unpermeabilized cells: both
isoforms traffic to the plasma membrane where they assemble into
polymeric filaments. (b) Permeabilized cells: V458L isoform is not
enriched in the ER compared to the wild type. Calnexin is shown as an
ER marker. (c) Western-blot detection of HA-tagged uromodulin
isoforms from the medium (M) and the soluble (L) and unsoluble (P)
fractions of lysates from stably transfected MDCK cells. While
pathogenic mutant C150S shows enrichment of the ER precursor, the
V458L isoform is not different from the wild type one.
doi:10.1371/journal.pone.0038311.g003
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